Systematic Review
Accepted on 28 Apr 2026
The benefit and risk of adding PD‑1/PD‑L1 inhibitors plus anti‑VEGF drugs to transarterial chemoembolisation for unresectable, non‑metastatic hepatocellular carcinoma: a pooled analysis of four RCTs
in Hepatobiliary Diseases